Tag Archives: cancer

‘He put himself through the wringer for me’ – stem cell transplant boost for Paul (35) facing cancer battle as brother is a match

Brotherly love certainly knows no bounds for one Co Tyrone family. s a fit young Strabane man faced a third battle with cancer, his four younger brothers immediately stepped in to help. Paul Carlin (35) is currently receiving treatment for non-Hodgkin’s lymphoma, an illness that he has faced down twice before. Despite receiving the all-clear… Read More »

Bowel cancer symptoms: The shape of your poo is a warning sign – when to see your GP

Processed meat is any meat that has been treated to preserve it and/or add flavour – for example, bacon, salami, sausages, canned meat, or chicken nuggets. “It is estimated that around 13 out of 100 bowel cancer cases (around 13 percent) in the UK are linked to eating these meats,” reports Cancer Research UK. Processed… Read More »

On-the-Job Exercise May Help Protect Against Heart Disease and Cancer

Advertisement Continue reading the main story Supported by Continue reading the main story Phys Ed On-the-Job Exercise May Help Protect Against Heart Disease and Cancer Men who had physically demanding jobs lived, on average, about a year longer than those who were deskbound. Credit…Desiree Rios for The New York Times June 2, 2021, 5:00 a.m.… Read More »

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the… Read More »

Johnson & Johnson snares FDA nod for first exon 20-targeted drug in EGFR lung cancer

Just a few short months after Johnson & Johnson’s Janssen unit sent its targeted non-small cell lung cancer drug amivantamab to the FDA, the regulator has come back with a green light—a very specific one. Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in… Read More »